Turing Pharma reduces cost of Daraprim in the USA

Privately-held drugmaker Turing Pharmaceuticals, via a statement from its Zug, Switzerland, office, unveiled significant price cuts for hospitals on Daraprim (pyrimethamine).

The company, and its USA-based chief executive Martin Shkreli, have come under a great deal of criticism and political approbation, after the company acquired rights to Daraprim from Impax Laboratories (The Pharma Letter August 10) and immediately raised the price from $13.50 per tablet to $750.

"Combined with our robust patient access programs, this is an important step in our commitment to ensure ready access to Daraprim at the lowest possible out-of-pocket cost for both hospitals and patients," said Nancy Retzlaff Turing's chief commercial officer adding: "We pledge that no patient needing Daraprim will ever be denied access."